期刊文献+

2-(咪唑并[1,2-a]吡啶-3-基)乙酸的制备

Synthesis of 2-(imidazopyridin-3-yl)acetic acid
下载PDF
导出
摘要 研究了一种用于治疗骨质疏松症药物的关键中间体米诺膦酸的制备方法。实验以二乙氧基膦酰乙酸乙酯和2,2-二甲氧基乙醛为起始原料,经维蒂希-霍纳反应、水解、环合、水解4步制备得到标题化合物。其熔点与1HNMR和文献报道的结果一致,总收率87.5%(以2-氨基吡啶计)。该方法克服了文献报道的工艺缺陷,与现有技术相比,后处理更简单,更适合工业化生产。 To study the preparation of the key intermediate of minnodronic acid,a drug which was used to the treatment of osteoporosis. The target compound was synthesized from tri- ethyl phosphonoaeetate and 2, 2-dimethoxyacetaldehyde via four steps through wittig-horner reaction, hydrolysis, cycliza- tion and hydrolysis. The melting point and I HNMR of final compound was in accordance with the literature, and the over- all yield of was 87.5%. Some drawbacks in the literature were improved and the method was easy for synthesis and suitable for industrial manufacturing.
出处 《化学试剂》 CAS CSCD 北大核心 2012年第6期565-566,共2页 Chemical Reagents
关键词 米诺膦酸 抗骨质疏松药物 2-(咪唑并[1 2-a]吡啶-3-基)乙酸 合成 minnodronic acid antiosteoporosis drug 2- ( imid-azo [ 1 , 2-a ] pyridin-3 -yl ) acetic acid synthesis
  • 相关文献

参考文献9

  • 1姚文瑾,范鸣.治疗骨质疏松症的新药米诺膦酸[J].药学进展,2009,33(11):526-527. 被引量:12
  • 2皮士卿,赵国庆,沈润溥,陈新志.米诺膦酸二钠的合成[J].中国医药工业杂志,2004,35(4):193-194. 被引量:19
  • 3杨利民.一种高纯度的米诺膦酸及其制备方法:CN,101531681A[P].2008-03-10.
  • 4苏贤斌,郭彦涛,聂菲.一种米诺膦酸关键中间体及其合成方法及由该中间体合成米诺膦酸的方法:CN,102093352A[P].2011-01-30.
  • 5牛帅,石创业,辛鹏凯,等.一种新的米诺膦酸关键中间体合成方法:CN,102101860A[P].2010-12-23.
  • 6周竞成.酒石酸唑吡坦的合成工艺研究[J].天津药学,2002,14(1):69-70. 被引量:9
  • 7ANN A P, JOCHEN A, PAUL B T. Kinase Inhibitora: WO ,2 003 076 398A2[ P]. 2003-09-18.
  • 8郑巍,孙逊.GSK3抑制剂的合成[J].复旦学报(自然科学版),2008,47(4):432-437. 被引量:1
  • 9SATOH T, HANAKI N, KURAMOCHI Y, et al. A new method for synthesis of allenes,including an optically ac- tive form, from aldehydes and alkenyl aryl sulfoxides by sulfoxide-metal exchange as the key reaction and an ap- plication to a total synthesis of male bean weevil sex at- tractant[ J]. Tetrahedron,2002,58:2 533-2 549.

二级参考文献16

  • 1[1]Isomura Y, Takeuchi M, Abe T. Heterocyclic bisphosphonic acid derivatives as bone resorption inhibitors [P]. EP: 354806,1990-02-14. (CA 1990, 113: 24240)
  • 2[2]Yoshida Y, Moriya A, Kitamura K, et al. Response of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction [J]. J Bone Miner Res, 1998, 13 (6): 1011-1022.
  • 3[3]Sasaki A, Kitimura K, Alcalde RE, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice [J]. Int J Cancer, 1998, 77 (2): 279-285.
  • 4[4]Almirante L, Mugnaini A, Friz LP, et al. Sintesi e reazioni di derivati dell' imidazolo[J]. Boll Chlm Farm, 1966, 105:32-43.
  • 5[5]Almiarante L. Synthesis and pharmacological activities of nitriles, amides, and carboxylic acid derivatives of imidazo [ 1,2-α] pyridine [J]. JMed Chem, 1969, 12 (1): 122-126.
  • 6Engler T A, Henry J R, Malhotra S, et al. Substituted 3-Imidazo [ 1,2-a] pyridin-3-yl-4-( 1,2,3,4-tetrahydro- [ 1,4 ] diazepino- [ 6,7,1- hi ] indol-7-yl) pyrrole-2,5-diones as highly selective and potent inhibi tors of Glycogen Synthase Kinase-3 [J] .J Med Chem ,2004,47(16) :3934-3937.
  • 7Ali A,Hoeflich K P,Woodgett J R. Glycogen synthase kinase-3, properties functions and regulation[J]. Chem Rev,2001,101:2527-2540.
  • 8Yao H B,Shaw P C,Wong C C, et al. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain [J]. J Chem Neuroanat, 2002,23 : 291-297.
  • 9Richard J. Inhibition of glycogen synthase kinase-3: a potential therapeutic target of lithium[J]. Clin Neurosci Res ,2004,4 : 171-179.
  • 10Grimes C A,Jope R S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling[J]. Pro Neurobiol,2001,65 : 391-426.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部